Page 372 - Fold News Today

I understand. but ive got to be clear. the president said you cant do anything with medicare social security and now he wants to bring that into the fold. we all heard that from all the people across the country over and over. >> so chris, it just gives you an example. house republicans have taken revenue raisers. closing tax loophole, raising taxes on the wealthy off the table. that leaves cuts mainly to domestic spending democratic priorities. if your recipe here is to put together a coalition...

Manifold Finance (FOLD) traded down 0.3% against the U.S. dollar during the 1 day period ending at 18:00 PM Eastern on May 23rd. Manifold Finance has a total market cap of $133.07 million and approximately $195,294.82 worth of Manifold Finance was traded on exchanges in the last 24 hours. One Manifold Finance token can currently […]

And he has occupied this unique position, in a way, of maintaining relations with both russia and ukraine, and that has put him in a position to be a broker. and he did help to broker the grain deal for exports from ukraine. but obviously his ongoing relationship with russia is seen as problematic by many in the west. president bashar al—assad, the mild—mannered former eye doctor whos become syrias strongman — the butcher of damascus, his enemies call him, is going from strength to strengt...

Manifold Finance (FOLD) traded down 2.1% against the US dollar during the 24-hour period ending at 0:00 AM Eastern on May 21st. One Manifold Finance token can currently be purchased for about $16.13 or 0.00060514 BTC on popular exchanges. Manifold Finance has a total market cap of $133.07 million and $383,498.92 worth of Manifold Finance […]

Its producing billions of dollars of income for the syrian regime, but also causing lots of problems for regional countries, especially saudi arabia. so is this therefore a way of easing various problems that syria is causing? bring assad back into the fold and then these problems can be addressed? well, perhaps they put it the other way around. they put it as a condition for assad to come back is to sort out these problems. but who are we talking to? were talking to a man who made promises over...

Sectoral Asset Management Inc. lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 11.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 507,682 shares of the biopharmaceutical company’s stock after selling 65,000 shares during the […]

Manifold Finance (FOLD) traded 3.8% lower against the U.S. dollar during the twenty-four hour period ending at 21:00 PM Eastern on May 20th. One Manifold Finance token can now be bought for about $16.53 or 0.00060674 BTC on popular exchanges. Manifold Finance has a market cap of $133.07 million and $343,542.57 worth of Manifold Finance […]

And he has occupied this unique position, in a way, of maintaining relations with both russia and ukraine, and that has put him in a position to be a broker. and he did help to broker the grain deal for exports from ukraine. but obviously his ongoing relationship with russia is seen as problematic by many in the west. president bashar al—assad, the mild—mannered former eye doctor whos become syrias strongman — the butcher of damascus, his enemies call him, is going from strength to strengt...

Its producing billions of dollars of income for the syrian regime, but also causing lots of problems for regional countries, especially saudi arabia. so is this therefore a way of easing various problems that syria is causing? bring assad back into the fold and then these problems can be addressed? well, perhaps they put it the other way around. they put it as a condition for assad to come back is to sort out these problems. but who are we talking to? were talking to a man who made promises over...

StockNews.com began coverage on shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) in a report published on Thursday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. The Goldman Sachs Group increased their price target on Amicus Therapeutics from $10.00 to […]